BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline. ・In the Absence cohort, patients experienced a median 73.1% reduction in seizures. ・The DEE cohort saw a ...

Levetiracetam reduces tonic-clonic seizures by over 77% in clinical studies. Ethosuximide is highly effective for absence seizures, especially in children. Valproate remains the gold standard for ...

Date and Time: January 6, 2026, 8AM ET Webcast: ...

Q: My child was staring off into space, and I thought he just wasn’t paying attention. He didn’t respond to his name and seemed frozen for about 10 seconds, then just resumed playing like nothing ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

New contributions to the field of epilepsy have opened a window into the cellular events that occur in the brain during absence seizures. At first, the teacher described her six-year-old student as ...

The electroencephalogram (EEG) provides important information to aid clinicians in the diagnosis of epilepsy. However, EEG techniques are associated with certain limitations, as discussed in the ...

Like many teenagers, Danielle Holton's first car was a ticket to freedom. At age 17, she bought a used Hyundai wagon from her mom, paying for it with money from her job as a certified nursing ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...